AU Patent

AU2023269182A1 — Immunotherapy of skin cancer using mpla-loaded hpg nanoparticles

Assigned to Yale University · Expires 2024-11-14 · 2y expired

What this patent protects

Encapsulation of MPLA in HPG-PLA nanoparticles having bioadhesive functional groups on the surface ("BNPs") prolongs the local antitumor immune response in melanoma and boosts the adaptive immune response conferred by MPLA due to the polymer's bioadhesive properties. Deli…

USPTO Abstract

Encapsulation of MPLA in HPG-PLA nanoparticles having bioadhesive functional groups on the surface ("BNPs") prolongs the local antitumor immune response in melanoma and boosts the adaptive immune response conferred by MPLA due to the polymer's bioadhesive properties. Delivery of MPLA in BNP prolongs the host's antitumor response with lower quantities of MPLA.Studies in mice showed that NPs delivered intratumorally have good lymphatic drainage and accumulate in lymph nodes, with prolonged dendritic cell maturation

Drugs covered by this patent

Patent Metadata

Patent number
AU2023269182A1
Jurisdiction
AU
Classification
—
Expires
2024-11-14
Drug substance claim
No
Drug product claim
No
Assignee
Yale University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.